Concizumab
- Generic Name
- Concizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1312299-39-0
- Unique Ingredient Identifier
- 68603V9EAF
- Background
Concizumab has been used in trials studying the treatment of Haemophilia A and Congenital Bleeding Disorder.
- Associated Conditions
- -
- Associated Therapies
- -
Post-Marketing Surveillance (All Case Surveillance) on Treatment With Alhemo® in Patients With Haemophilia A or Haemophilia B With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2024-02-29
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 23
- Registration Number
- NCT06285071
- Locations
- 🇯🇵
Mutsu general hospital, Aomori, Japan
🇯🇵Novo Nordisk Investigational Site, Toshima, Tokyo, Japan
🇯🇵Sapporo Tokushukai Hospital_Pediatrics, Hokkaido, Japan
A Research Study on How Well Concizumab Works for You if You Have Haemophilia A or B With or Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2021-11-26
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 90
- Registration Number
- NCT05135559
- Locations
- 🇺🇸
Children's Nebraska, Omaha, Nebraska, United States
🇺🇸Rady Childrens Hosp San Diego, San Diego, California, United States
🇺🇸Arnold Palmer Children's Hospital, Orlando, Florida, United States
Compassionate Use of Concizumab if You Have Haemophilia
- Conditions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Novo Nordisk A/S
- Registration Number
- NCT04921956
- Locations
- 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸Southern Specialty Clinic, Flowood, Mississippi, United States
🇺🇸ECU Sickle Cell Comp Clinic, Greenville, North Carolina, United States
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-09-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 136
- Registration Number
- NCT04083781
- Locations
- 🇯🇵
St. Marianna University School of Medicine Hospital_Pediatrics, Kanagawa, Japan
🇯🇵Nara Medical University Hospital_Pediatrics, Nara, Japan
🇯🇵Saitama Medical Univ. Hospital, Saitama, Japan
Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2019-09-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 158
- Registration Number
- NCT04082429
- Locations
- 🇭🇺
MH Eü. Központ -Orszagos Haemophilia Kozpont, Budapest, Hungary
🇮🇳St. John's Medical college and Hospital, Bangalore, Karnataka, India
🇮🇳Sahyadri Speciality Hospital, Pune, Maharashtra, India
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 36
- Registration Number
- NCT03196297
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors
- Conditions
- Interventions
- First Posted Date
- 2017-06-22
- Last Posted Date
- 2021-10-22
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 26
- Registration Number
- NCT03196284
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Sheffield, United Kingdom
Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
- Conditions
- Interventions
- First Posted Date
- 2015-07-07
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT02490787
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Southampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.